HR and breast carcinoma: CDK4/6 inhibitors such as palbociclib, ribociclib, and abemaciclib are approved by the Food and Drug Administration and European Medicines Agency for use in breast cancer (HR+/HER2−) when combined with hormonal therapeutics (13).